Organon & Co
USUSDOrganon & Co (LSE:0A9W) — Biotechnology: Pharmaceutical Preparations. Numărul de burse pe care se tranzacționează acțiunile companiei: 2. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.
Despre Companie
- Site Web
- organon.com
- Relații cu Investitorii
- organon.com/investor-relations/
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sediu Central
- Oss, United States
- Director General
- Joseph T. Morrissey
- Angajați
- 10 000
- Fondată
- 1923
- Acțiuni în Circulație
- Free Float
- 242.99 mil.
- Capitalizare de Piață
- 3.6 mld. USD
- Insideri
- 0.46%
- Investitori Instituționali
- 84.8%
- Industrie (SIC)
- Pharmaceutical Preparations
- ISIN
- US68622V1061
- LEI
- 549300AMCKY57OK2CO56
- Rata de Distribuire
- 8.6%
- FCF
- 567 mil. USD
- Plăți / FCF
- 3%
- Datorie
- 8.55 mld. USD13 ani FCF
- Vechimea Dividendelor
- 5 ani
- Câștiguri, FCF și dividende plătite — pentru cele 12 luni până la 30.06.2026 (cel mai recent raport al companiei).
- NAV
Descriere
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Dividende
Organon & Co (0A9W) plătește dividende trimestrial. Pe an (12 luni până la și inclusiv cea mai recentă plată anunțată): 0.08 USD pe acțiune (plăți: 4). Aceasta reprezintă aproximativ 0.58% din prețul actual al acțiunilor. Pe baza istoricului plăților, următoarea dată ex-dividend este așteptată în jurul datei de 17.11.2026. Istoric neîntrerupt al dividendelor: 5 ani.
| Data Ex | Plată | Sumă | % | Tip | Simbol |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-09-10 | 0.0200 USD | 0.1/0.6 % | trimestrial | LSE:0A9W |
| 2026-05-11 | 2026-06-11 | 0.0200 USD | 0.2/0.6 % | trimestrial | LSE:0A9W |
| 2026-02-23 | 2026-03-12 | 0.0200 USD | 0.3/1.0 % | trimestrial | LSE:0A9W |
| 2025-11-20 | 2025-12-11 | 0.0200 USD | 0.3/4.6 % | trimestrial | LSE:0A9W |
| 2025-08-15 | 2025-09-11 | 0.0200 USD | 0.2/6.5 % | trimestrial | LSE:0A9W |
| 2025-05-12 | 2025-06-12 | 0.0200 USD | 0.2/9.7 % | trimestrial | LSE:0A9W |
| 2025-02-21 | 2025-03-13 | 0.2800 USD | 1.8/7.2 % | trimestrial | LSE:0A9W |
| 2024-11-12 | 2024-12-12 | 0.2800 USD | 1.5/6.0 % | trimestrial | LSE:0A9W |
| 2024-08-16 | 2024-09-12 | 0.2800 USD | 1.5/6.0 % | trimestrial | LSE:0A9W |
| 2024-05-10 | 2024-06-13 | 0.2800 USD | 1.5/6.0 % | trimestrial | LSE:0A9W |
| 2024-02-23 | 2024-03-14 | 0.2800 USD | 1.5/6.0 % | trimestrial | LSE:0A9W |
| 2023-11-10 | 2023-12-14 | 0.2800 USD | 2.4/9.8 % | trimestrial | LSE:0A9W |
| 2023-08-17 | — | 0.2800 USD | 1.2/4.9 % | trimestrial | LSE:0A9W |
| 2023-05-12 | — | 0.2800 USD | 1.3/5.3 % | trimestrial | LSE:0A9W |
| 2023-02-24 | — | 0.2800 USD | 1.1/4.2 % | trimestrial | LSE:0A9W |
| 2022-11-10 | — | 0.2800 USD | 1.2/4.7 % | trimestrial | LSE:0A9W |
| 2022-08-12 | — | 0.2800 USD | 0.9/3.5 % | trimestrial | LSE:0A9W |
| 2022-05-13 | — | 0.2800 USD | 0.8/2.4 % | trimestrial | LSE:0A9W |
| 2022-02-25 | — | 0.2800 USD | 0.8/1.6 % | trimestrial | LSE:0A9W |
| 2021-11-19 | — | 0.2800 USD | 0.9/0.9 % | trimestrial | LSE:0A9W |
Cei Mai Mari Acționari
| Deținător | Participație | Acțiuni | Data Raportului |
|---|---|---|---|
| Blackrock Inc. | 12.21% | 32.06 mil. | 2026-06-30 |
| Pentwater Capital Manage… | 6.89% | 18.1 mil. | 2026-06-30 |
| iShares Trust-iShares Co… | 6.09% | 16 mil. | 2026-08-31 |
| Vanguard Portfolio Manag… | 5.76% | 15.13 mil. | 2026-06-30 |
| Vanguard Capital Managem… | 4.54% | 11.91 mil. | 2026-06-30 |
| State Street Corporation | 3.68% | 9.66 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 8.33 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.29% | 6.02 mil. | 2026-06-30 |
| Goldman Sachs Group Inc | 1.98% | 5.2 mil. | 2026-06-30 |
| UBS Group AG | 1.85% | 4.86 mil. | 2026-06-30 |
| Geode Capital Management… | 1.83% | 4.82 mil. | 2026-06-30 |
| Alliancebernstein L.P. | 1.81% | 4.75 mil. | 2026-06-30 |
| Man Group PLC | 1.59% | 4.18 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.45% | 3.82 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 3.01 mil. | 2026-06-30 |
| NexPoint Funds I-NexPoin… | 1.03% | 2.71 mil. | 2026-06-30 |
| SPDR SERIES TRUST-State… | 0.94% | 2.47 mil. | 2026-08-31 |
| iShares Trust-iShares S&… | 0.89% | 2.35 mil. | 2026-08-31 |
| SPDR SERIES TRUST-State… | 0.54% | 1.41 mil. | 2026-08-31 |
| Fidelity Concord Street… | 0.49% | 1.3 mil. | 2026-07-31 |
| ALI KEVIN (Chief Executi… | ≈0.11% | 282 731 | 2025-05-05 |
| WALSH MATTHEW M (Chief F… | ≈0.08% | 212 746 | 2026-03-31 |
| MORRISSEY JOSEPH T JR (C… | ≈0.05% | 123 123 | 2026-03-31 |
| STAHLER RACHEL A (Chief… | ≈0.04% | 116 105 | 2026-03-31 |
| FALCIONE AARON (Officer) | ≈0.04% | 101 431 | 2026-03-31 |
| WEAVER KIRKE (General Co… | ≈0.04% | 92 639 | 2026-03-31 |
| NISITA VITTORIO (Officer… | ≈0.03% | 70 619 | 2026-03-31 |
| KARP DANIEL (Officer) | ≈0.03% | 69 547 | 2026-03-31 |
| HOLZBAUR LYNETTE (Office… | ≈0.02% | 52 850 | 2026-05-06 |
| COX CARRIE SMITH (Office… | — | — | 2025-11-12 |
